Of note, 82% had a PD-L1 tumor proportion score (TPS) <50%, and 67% had received a chemotherapy doublet plus pembrolizumab as the previous line, representing a more challenging and likely immune-exhausted population [38]. Here, CD274 is linked to neoplasm.